Company Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease.
Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics.
Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 1989 |
| IPO Date | Jul 24, 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6,100 |
| CEO | Reshma Kewalramani |
Contact Details
Address: 50 Northern Avenue Boston, Massachusetts 02210 United States | |
| Phone | 617-341-6100 |
| Website | vrtx.com |
Stock Details
| Ticker Symbol | VRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000875320 |
| CUSIP Number | 92532F100 |
| ISIN Number | US92532F1003 |
| Employer ID | 04-3039129 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Reshma Kewalramani FASN, M.D. | Chief Executive Officer, President and Director |
| Dr. Jeffrey Marc Leiden M.D., Ph.D. | Executive Chairman |
| Charles F. Wagner Jr. | Executive Vice President and Chief Financial Officer |
| Stuart A. Arbuckle B.Sc. | Executive Vice President and Chief Operating Officer |
| Dr. David M. Altshuler M.D., Ph.D. | Executive Vice President and Chief Scientific Officer |
| Kristen C. Ambrose CPA | Senior Vice President and Chief Accounting Officer |
| Mike Tirozzi | SVice President and Chief Information and Data Officer |
| Susie Lisa C.F.A. | Senior Vice President of Investor Relations |
| Jonathan Biller J.D. | Executive Vice President and Chief Legal Officer |
| Nina Devlin | Senior Vice President and Chief Communications Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2025 | 144 | Filing |
| Feb 18, 2025 | 144 | Filing |
| Feb 18, 2025 | 144 | Filing |
| Feb 13, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | 10-K | Annual Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | 144 | Filing |
| Feb 11, 2025 | 144 | Filing |
| Feb 11, 2025 | 144 | Filing |